Interleukin-10 fails to modulate low shear stress-induced neointimal hyperplasia.

INTRODUCTION Overexpression of the anti-inflammatory cytokine interleukin-10 (IL-10) blocks atherosclerotic events in vivo, and IL-10 has been recently hailed as an "immunologic scalpel" for atherosclerosis. Alternatively, mice lacking IL-10 receiving atherogenic diets have increased occlusive lesions. It remains unclear whether such IL-10 modulation broadly applies to other forms of occlusive arterial remodeling. We hypothesized that lack of IL-10 would exacerbate, and exogenous or overexpression of IL-10 would abrogate low shear stress-induced neointimal hyperplasia (NIH). METHODS Wild-type (WT) and IL-10-deficient (IL-10-/-) mice underwent unilateral common carotid artery (CCA) ligation. Low shear stress in the patent ligated artery results in remodeling and formation of neointima containing BrdU and SMC alpha-actin-positive cells. Additional groups of WT mice underwent CCA ligation and were treated daily with intraperitoneal saline or 1 microg of human IL-10. Chronic delivery gene therapy approaches were also utilized to define the role of IL-10 signaling. WT mice were treated adventitially with 1 x 10(10) adenovirus/green fluorescent protein (Ad/gfp) and an Ad/empty control to confirm the veracity of adventitial delivery. Then, Ad viral IL-10 (vIL-10), Ad/empty, and virus buffer alone were applied directly to the adventitia of the CAA immediately following ligation. In separate experiments, 1 x 10(10) Ad/empty or Ad/vIL-10 was injected intramuscularly. CCAs were perfusion fixed 28 days postligation, the time at which NIH is near maximum. RESULTS IL-10-/- mice developed identical NIH areas compared to WT controls. Mice receiving IL-10 demonstrated NIH equivalent to saline controls. Mice receiving intramuscular or adventitial Ad/IL-10 developed high serum levels of IL-10 yet formed NIH areas similar to those of controls. Serum IL-10 levels were significantly higher (P = 0.04) with adventitial delivery. Mice treated adventitially with Ad/gfp showed reliable transfection of cells within the adventitia of CAA. No antibody to human IL-10 was found in the sera of intraperitoneal IL-10-treated mice, which failed to attenuate NIH. CONCLUSION Under the conditions of this experiment, lack of IL-10 does not exacerbate low shear stress-induced NIH, nor does exogenous administration or overexpression of IL-10 attenuate it. Despite high serum levels of vIL-10 in mice treated with ad/vIL-10 adventitially, there appears to be no therapeutic effect despite the confirmed transfection of adventitial cells. Discrepancies between these findings and previous research may be related to IL-10 dosing, inflammation induced by the adenoviral vector, or disparities between the NIH models.

[1]  J. Vermylen,et al.  Mouse Carotid Artery Ligation Induces Platelet-Leukocyte–Dependent Luminal Fibrin, Required for Neointima Development , 2001, Circulation research.

[2]  L. Moldawer,et al.  Extended lung expression and increased tissue localization of viral IL-10 with adenoviral gene therapy. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Moldawer,et al.  Direct Evidence for Cytokine Involvement in Neointimal Hyperplasia , 2000, Circulation.

[4]  D. Rennick,et al.  XII. IL-10-deficient (IL-10− / −) mice and intestinal inflammation * , 2000 .

[5]  L. Moldawer,et al.  ANTICYTOKINE THERAPIES FOR ACUTE INFLAMMATION AND THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: IL‐10 AND ISCHEMIA/REPERFUSION INJURY AS A NEW PARADIGM , 2000, Shock.

[6]  M. Ziol,et al.  Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. , 2000, Circulation.

[7]  L. Moldawer,et al.  TNF-α Receptor Signaling and IL-10 Gene Therapy Regulate the Innate and Humoral Immune Responses to Recombinant Adenovirus in the Lung1 , 2000, The Journal of Immunology.

[8]  M. Territo,et al.  Interleukin-10 blocks atherosclerotic events in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[9]  R. Terkeltaub IL-10: An "immunologic scalpel" for atherosclerosis? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[10]  M. Bureau,et al.  Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.

[11]  D. Dichek,et al.  Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors. , 1999, Journal of vascular surgery.

[12]  A. Tedgui,et al.  Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[13]  S. Opal,et al.  Interleukin-10: potential benefits and possible risks in clinical infectious diseases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  E. Keystone,et al.  IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. , 1998, Rheumatic diseases clinics of North America.

[15]  A. Tedgui,et al.  Signal transduction of mechanical stresses in the vascular wall. , 1998, Hypertension.

[16]  G. Rogler,et al.  Cytokines in Inflammatory Bowel Disease , 1998, World Journal of Surgery.

[17]  L. Moldawer,et al.  Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. , 1998, Journal of applied physiology.

[18]  R. McIntyre,et al.  Interleukin-10 inhibits human vascular smooth muscle proliferation. , 1998, Journal of molecular and cellular cardiology.

[19]  R. Ross,et al.  Atherosclerosis is an Inflammatory Disease , 1998 .

[20]  V. Lindner,et al.  Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. , 1997, Circulation.

[21]  Amit Kumar,et al.  Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[22]  H. Perlman,et al.  Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. , 1997, Circulation.

[23]  D. Alarcón-Segovia,et al.  Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. , 1997, Journal of immunology.

[24]  P. Libby,et al.  The molecular bases of restenosis. , 1997, Progress in cardiovascular diseases.

[25]  L. Moldawer,et al.  Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. , 1997, Journal of vascular surgery.

[26]  Y. Yazaki,et al.  Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs. , 1997, Journal of cardiovascular pharmacology.

[27]  J. Banchereau,et al.  The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. , 1997, Journal of immunology.

[28]  P. Hart,et al.  Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. , 1996, Journal of immunology.

[29]  B L Langille,et al.  Cellular and molecular biology of vascular remodeling , 1996, Current opinion in lipidology.

[30]  S M Schwartz,et al.  The intima. Soil for atherosclerosis and restenosis. , 1995, Circulation research.

[31]  P. Davies,et al.  Flow-mediated endothelial mechanotransduction. , 1995, Physiological reviews.

[32]  A. Gotlieb,et al.  Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. , 1995, British heart journal.

[33]  F. Graham,et al.  Methods for construction of adenovirus vectors , 1995, Molecular biotechnology.

[34]  M. Feldmann,et al.  Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes , 1994, European journal of immunology.

[35]  H. Shepard,et al.  Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. , 1994, Human gene therapy.

[36]  F. Calzetti,et al.  Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation , 1994, The Journal of experimental medicine.

[37]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[38]  P. Davies,et al.  Hemodynamic forces and vascular cell communication in arteries. , 1992, Archives of pathology & laboratory medicine.

[39]  M. Gimbrone,et al.  Vascular endothelium responds to fluid shear stress gradients. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[40]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[41]  T. Mosmann,et al.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  T. Mosmann,et al.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.

[43]  B L Langille,et al.  Adaptations of carotid arteries of young and mature rabbits to reduced carotid blood flow. , 1989, The American journal of physiology.

[44]  P. Libby,et al.  Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. , 1989, Journal of immunology.

[45]  S. Narula,et al.  Immunomodulation of Crohn's disease by interleukin-10. , 1998, Agents and actions. Supplements.

[46]  S. V. van Deventer,et al.  Immunotherapy of Crohn's disease. , 1998, Mediators of inflammation.

[47]  P. Libby,et al.  Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque , 1995, Journal of cardiovascular pharmacology.

[48]  P. Libby,et al.  Cytokines as mediators of vascular pathology. , 1992, Nouvelle revue francaise d'hematologie.